Early Access — free while we kick the tires
EdgarHawk

Haveli Investments, LP

Director

Director 10% Owner

Latest: Director buying · June 2026

17 filings analyzed · 1 company · Latest 2026-06-15

Companies

Company Buys Sells Direction
Blend Labs, Inc. BLND 40 0 Net buying

Activity

June 2026
2026-06-15 Blend Labs, Inc. BLND
high
Buy
1,156,928 shares
$1,991,366
Significance 6/10

Haveli Investments (Director) purchased 1,156,928 shares across 3 trades for $1,991,365.97, raising stake to 18.69M shares amid -23.7% revenue decline and unprofitable operations.

Haveli Investments acquired 1,156,928 shares across three separate transactions (June 11–15, 2026) at prices ranging from $1.70 to $1.74, representing a 6.6% increase in its stake to 18.69M shares. The timing is notable: BLND's stock is down 62.6% from its 52-week high of $4.49 and trades at $1.68 versus the blended transaction price of $1.72. The underlying business context is concerning—quarterly revenue is $30.8M with a net loss of $8.0M, and annual revenue contracted 23.7% year-over-year while the company remains unprofitable. The insider's broader track record shows 20 prior cross-ticker buys averaging +12.0% 30-day returns but a 0.00% 90-day win rate with -45.3% average 90-day returns, suggesting execution challenges in longer-dated outcomes. At this specific ticker, five consecutive buy trades occurred between June 3–10 (outcomes not yet measurable), and no prior buys at BLND were well-timed at the 90-day mark. The volume and frequency of purchases into a deteriorating business backdrop—combined with a track record of poor 90-day outcomes—presents a mixed signal for investors.

2026-06-10 Blend Labs, Inc. BLND
high
Buy
1,118,935 shares
$1,882,391
Significance 7/10

Director Haveli Investments LP buys 1,118,935 shares across 3 trades (avg $1.68) while stock trades -63.0% from 52-week high

Haveli Investments LP executed 3 separate purchases totaling 1,118,935 shares for $1,882,390.91 at an average price of $1.68 per share between June 8-10, 2026, increasing its stake by 6.8% to 17,536,729 shares. The timing is notable: the purchases occurred as BLND traded at $1.66 (current), down 63.0% from its 52-week high of $4.49, yet the insider's 5 prior purchases at this ticker (May 20-27) all posted positive 90-day returns (ranging 14.7% to 17.9%), suggesting a historical pattern of well-timed entry points at BLND. Against this backdrop, the company faces material headwinds—annual revenue declined 23.7% year-over-year, the latest quarter showed net income of $-8.0M on revenue of $30.8M, and the company remains unprofitable—which amplifies the significance of the director's continued accumulation despite depressed valuation and deteriorating fundamentals.

2026-06-05 Blend Labs, Inc. BLND
high
Buy
268,606 shares
$421,335
Significance 7/10

Haveli Investments LP (Director) purchased 268,606 shares of BLND for $421,334.82 across 2 transactions at avg $1.57, raising stake to 16.42M shares.

Haveli Investments, LP acquired 268,606 shares totaling $421,334.82 at blended average price $1.57 during June 2026, expanding its stake by 1.7% to 16.42M shares post-transaction. BLND trades at $1.62 currently, representing a -63.9% drawdown from the 52-week high of $4.49, while the company reported revenue of $30,843,000.00 and net loss of $-8,049,000.00 in its latest quarter, with full-year net income negative and annual revenue declining -23.7% year-over-year. The filer's same-ticker purchase history at BLND shows 5 prior buys (2026-05-20 through 2026-05-27) that were each positive at the 90-day mark, ranging from +14.7% to +17.9%, establishing a pattern of well-timed accumulation at this ticker. This filing represents a continuation of that pattern through two separate purchases on 2026-06-03 and 2026-06-05, executed after a period of sustained buying activity.

May 2026
2026-05-27 Blend Labs, Inc. BLND
high
Buy
1,043,628 shares
$1,540,215
Significance 7/10

Haveli Investments buys 1,043,628 shares in 3 transactions at blended avg $1.48; stock now $1.56, -65.3% from 52-week high.

Haveli Investments, LP executed 3 separate purchases totaling 1,043,628 shares for $1,540,214.88 between May 22–27, 2026, at a blended average price of $1.48, lifting holdings to 16,149,188 shares. The current price of $1.56 sits -65.3% from the 52-week high of $4.49, and the stock has gained +10.6% over the past 30 days despite a -10.3% 90-day decline. Across the insider's 5 prior purchases at BLND (May 12–18), all posted positive 90-day returns, ranging from +4.0% to +15.4%, establishing a consistent pattern of well-timed entries at this ticker. However, the company remains unprofitable (net income $-8,049,000.00 in the latest quarter) with annual revenue declining -23.7%, creating a tension between the insider's demonstrated trading accuracy at this stock and the deteriorating business fundamentals that may explain the steep discount relative to recent highs.

2026-05-21 Blend Labs, Inc. BLND
high
Buy
777,178 shares
$1,158,140
Significance 7/10

Director Haveli Investments bought 777.2K shares at $1.49 avg across 3 trades, raising stake to 15.11M shares (+5.4%); stock down -66.2% from 52-week high.

Haveli Investments, a director, purchased 777,178 shares totaling $1,158,139.78 across three separate transactions on May 19–21, 2026, at prices of $1.49–$1.50 per share. This increased the filer's total holdings from 14,328,382 shares to 15,105,560 shares. The stock is currently trading at $1.52, which represents a -66.2% decline from its 52-week high of $4.49, and has fallen -10.6% over the past 90 days. At the company level, BLND reported a latest-quarter revenue of $30,843,000.00 and net income of $-8,049,000.00, with annual revenue declining -23.7% year-over-year; the company remains unprofitable. Notably, the filer's five prior purchases at this ticker (all in early May 2026) showed strong forward returns, with 90-day outcomes of +4.0%, +5.6%, +15.4%, +6.3%, and +8.2% across those buys.

2026-05-18 Blend Labs, Inc. BLND
medium
Buy
1,527,874 shares
$2,090,274
Significance 6/10

Haveli Investments LP accumulated 1,527,874 shares of BLND at $1.37 blended average across 3 purchases; prior 5 BLND trades all underwater at 90-day mark.

Haveli Investments, LP (Director) executed 3 separate purchases totaling 1,527,874 shares for $2,090,273.60 between May 14–18, 2026, at prices ranging from $1.33 to $1.47. The director's prior 5 purchases at BLND all generated negative 90-day returns (ranging from -44.2% to -47.1%), with zero instances of well-timed entry at the 90-day measurement. The company is unprofitable (net income $-8,049,000.00 in latest quarter) and has contracted -23.7% in annual revenue, providing limited fundamental support for accumulation. Current price is $1.58, representing -64.8% decline from the 52-week high of $4.49, and these latest purchases at $1.37 already appear underwater relative to near-term price action (52-week range $1.18–$4.49), mirroring the outcome pattern of the director's 5 preceding BLND acquisitions.

2026-05-13 Blend Labs, Inc. BLND
high
Buy
1,951,635 shares
$2,789,590
Significance 6/10

Haveli Investments, 10% owner, acquires nearly 2M shares at depressed prices amid company's revenue decline and losses.

Haveli Investments, a 10% beneficial owner and director of Blend Labs, purchased nearly two million shares across three consecutive days in May, expanding its indirect holdings by approximately 18% to over twelve million shares. The purchases occurred while the stock trades well below its 52-week high and near its 52-week low, suggesting the institutional holder is buying into substantial weakness. The company's financials show declining revenue and persistent losses, creating a backdrop of operational pressure that makes large-scale open-market accumulation a notable move by a major shareholder. This is the eighth open-market purchase by Haveli at Blend in the 36-month window—part of a sustained buying pattern—yet prior purchases at this ticker have uniformly declined in value afterward, with all five previous trades showing losses both in the short and long term, raising questions about the timing and thesis behind this continued accumulation.

December 2025
2025-12-03 Blend Labs, Inc. BLND
high
Buy
1,309,823 shares
$4,068,721
Significance 6/10

Haveli Investments (Director) purchased 1,309,823 shares at $3.11 avg across 3 transactions totaling $4,068,721.26

Haveli Investments filed 3 separate open-market purchases totaling 1,309,823 (1.31M shares) for $4,068,721.26 between 2025-12-01 and 2025-12-03 at a blended average price of $3.11, increasing holdings by 13.7% to 10,848,873 shares post-transaction. The purchases occur within the 52-week trading range ($2.73–$5.35), with the stock currently at $3.10, down 42.1% from its 52-week high and down 4.6% over 30 days. Notably, Haveli Investments has already executed 5 prior acquisitions at BLND within the past two weeks (2025-11-17 through 2025-11-26), continuing an aggressive accumulation pattern at this price level. Across the insider's broader cross-ticker history, the track record shows 17 prior buys with an 85.71% 90-day win rate and average 90-day return of +13.0%, though measurable outcomes for the recent BLND trades remain pending. The company's fundamentals show recent quarterly revenue of $32,860,000.00 and net income of $12,532,000.00, though full-year profitability remains negative, suggesting recovery dynamics are uncertain.

November 2025
2025-11-26 Blend Labs, Inc. BLND
high
Buy
69,934 shares
$213,850
Significance 6/10

Haveli Investments (Director) purchased 69,934 shares at $3.06 avg in 2 transactions; holds 9.54M shares post-trade

Haveli Investments, L.P. executed two separate open-market purchases totaling 69,934 shares for $213,850.28 at a blended average price of $3.06 on 2025-11-24 and 2025-11-26, increasing holdings from 9.47M to 9.54M shares (+0.7%). The transaction occurred in a notably depressed context: BLND trades at $3.13, down 41.5% from its 52-week high of $5.35 and down 11.8% over the trailing 30 days. The insider's cross-ticker track record shows strong historical outcomes (15 prior buys, 85.71% 90-day win rate, avg 90d return +13.0%), though this provides limited directional signal for a single-ticker holding already representing the bulk of a concentrated position. What warrants investor attention is the composition of the timing and volume pattern: five separate buys at BLND within a 12-day window (2025-11-13 through 2025-11-19, plus the two disclosed here on 2025-11-24 and 2025-11-26) suggest sustained capital deployment into the stock during a period of sharp near-term decline, even as the company posted modest annual revenue growth (+3.3%) and reported full-year net income negative despite recent quarterly profitability ($12.5M net income in latest quarter on $32.9M revenue).

2025-11-20 Blend Labs, Inc. BLND
high
Buy
1,382,197 shares
$4,193,929
Significance 7/10

Haveli Investments (Director) purchased 1,382,197 shares in two transactions at $3.05 and $3.03 (totaling $4,193,929.03) on 2025-11-18 to 2025-11-19, lifting holdings to 9,469,116 shares.

Haveli Investments filed two separate purchases totaling 1,382,197 shares for $4,193,929.03 at a blended average price of $3.03, executed on consecutive days (2025-11-18 and 2025-11-19). The transaction represents a +17.1% increase to the director's pre-existing 8,086,919 share position, signaling material capital commitment to Blend Labs at current levels. This activity follows a cluster of four prior purchases at the same ticker within the preceding week (2025-11-11 through 2025-11-17), all outcomes unmeasurable to date. Notably, the current price of $2.84 reflects a -46.9% decline from the 52-week high of $5.35, and the stock has fallen -18.4% over the past 30 days and -22.8% over 90 days—timing that places these purchases substantially below recent trading ranges. Across the director's cross-ticker historical record, prior open-market buys averaged +23.3% 30-day returns and +13.0% 90-day returns with an 85.71% win rate, though same-ticker outcomes at BLND remain too recent to evaluate.

Related insiders

Create a free account

Build watchlists, get email alerts on the tickers you follow, and read the full AI analysis on every insider filing.

Sign up — free during early access